US equities |
AAPL $329.83 ▼-2.51% MU $869.31 ▲+4.29% NVDA $208.98 ▲+3.43% PLTR $171.43 ▼-3.87% ORCL $123.90 ▲+3.93% SNDK $1,143.46 ▲+6.36% AMD $493.75 ▲+5.76% SPCX $139.90 ▲+2.58%
FinancialContent

Articles published by Remix Therapeutics

News headline image
Remix Therapeutics Selected for Late-Breaking Oral Presentation at the 38th EORTC-NCI-AACR Symposium
From Remix Therapeutics
Via GlobeNewswire
News headline image
Remix Therapeutics™ Appoints Michael Landsittel to Board of Directors
From Remix Therapeutics
Via GlobeNewswire
News headline image
Remix Therapeutics Appoints Nicole Sweeny as Chief Commercial Officer
From Remix Therapeutics
Via GlobeNewswire
News headline image
Remix Therapeutics to Participate in Upcoming Investor Conferences
From Remix Therapeutics
Via GlobeNewswire
News headline image
Remix Therapeutics to Present at 46th Annual Canaccord Genuity Growth Conference
From Remix Therapeutics
Via GlobeNewswire
News headline image
Remix Therapeutics to Present at AACR Drug Discovery and Development Conference
From Remix Therapeutics
Via GlobeNewswire
News headline image
Remix Therapeutics Announces Positive Data from Phase 1/2 ARIA Study of First-in-Class MYB mRNA Degrader, REM-422, in Patients with Adenoid Cystic Carcinoma (ACC) at the American Society of Clinical Oncology Annual Meeting 2026
From Remix Therapeutics
Via GlobeNewswire
News headline image
Remix Therapeutics Announces Oral Presentation of First-in-Class Small Molecule MYB mRNA Degrader REM-422 Phase 1/2 ARIA Trial Results at the 2026 American Society of Clinical Oncology Annual Meeting
From Remix Therapeutics
Via GlobeNewswire
News headline image
Remix Therapeutics Appoints Mythili Koneru, MD, PhD, as Chief Medical Officer
From Remix Therapeutics
Via GlobeNewswire
News headline image
Remix Therapeutics to Present at Guggenheim Second Annual Healthcare Innovation Conference
From Remix Therapeutics
Via GlobeNewswire
News headline image
Remix Therapeutics Announces Positive Preliminary Data from Phase 1 Study of REM-422 in Patients with Adenoid Cystic Carcinoma at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Remix Therapeutics
Via GlobeNewswire
News headline image
Remix Therapeutics to Present Phase 1 Data of REM-422 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Conference in Late-Breaking Oral Presentation
From Remix Therapeutics
Via GlobeNewswire
News headline image
Remix Therapeutics Appoints Linda C. Bain to Board of Directors
From Remix Therapeutics
Via GlobeNewswire
News headline image
Remix Therapeutics to Present at Stifel 2025 Virtual Targeted Oncology Forum
From Remix Therapeutics
Via GlobeNewswire
News headline image
Remix Therapeutics Announces Participation in Leerink Global Healthcare Conference
From Remix Therapeutics
Via GlobeNewswire
News headline image
Remix Therapeutics to Present at 5th Annual RNA-Targeted Drug Discovery Summit
From Remix Therapeutics
Via GlobeNewswire